In­cyte ax­es blood can­cer col­lab with Sy­ros

In­cyte de­cid­ed not to ad­vance its blood can­cer col­lab­o­ra­tion with Sy­ros Phar­ma­ceu­ti­cals in an­oth­er blow to the biotech’s part­ner­ship port­fo­lio.

In­cyte gave no­tice Aug. 9 that it would end its myelo­pro­lif­er­a­tive neo­plasms part­ner­ship with the Cam­bridge, MA-based biotech with­in 60 days. Ac­cord­ing to an SEC fil­ing on Aug. 11, Sy­ros said “In­cyte ex­er­cised its right to ter­mi­nate the agree­ment for con­ve­nience.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER